Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRGF eye drops vs Hyabak for dry eye disease in patients with glaucoma
2022-001662-35Phase 3Active
- Sponsor
- BTI Biotechnology Institute
- Start
- Jun 2022
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of PRGF-Endoret in dry eye syndrome (DED) (2 arms), sponsored by BTI Biotechnology Institute. Primary endpoint: Change in ocular staining at 6 months. Started Jun 2022; status: active.
02
Drugs
PRGF-Endoret
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on 2022-001662-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001662-35.